+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 90 Actively Recruiting clinical trials

B

Actively Recruiting

Healthy Volunteer

This study evaluates the immediate and long-term effects of structured breathing exercises on mental health symptoms such as anxiety, depression, perceived stress, and sleep quality in healthcare professionals. The research aims to understand how breathing practices might support mental well-being and resilience in this population. Participants will engage in self-guided structured breathing sessions lasting 15, 30, or 36 minutes, tailored to their personal skill level. These sessions are designed to improve brain circulation and mental well-being. The study uses a single group design without a comparison group, focusing on this breathing intervention over a four-month period. Throughout the study, participants will use a mobile app to track adherence, engagement, and satisfaction with the breathing exercises. Researchers will assess feasibility through recruitment ease, retention rates, and intervention acceptability. Mental health outcomes and participant feedback will be collected at regular intervals during the four months of study participation.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
4 locations
T

Actively Recruiting

Researchers are evaluating intensity-modulated post-operative radiation therapy I-PORT combined with standard chemotherapy or immunotherapy versus standard therapy alone for patients with non-small cell lung cancer NSCLC who have remaining lymph node cancer after surgery. This phase II trial aims to determine if I-PORT improves disease-free survival and assesses its impact on severe late cardiopulmonary side effects compared to standard care. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy or immunotherapy alone, while the other undergoes I-PORT daily Monday through Friday over 5 to 6 weeks, starting 4 to 12 weeks after surgery, followed by standard therapy. Throughout the study, patients have CT andor MRI scans, FDG-PET scans, and blood samples collected. Treatment continues until disease progression or unacceptable side effects occur. After completing treatment, participants are followed every 3 months for 2 years and then every 6 months for an additional 3 years. The study measures disease-free survival up to 5 years, overall survival at 2 and 5 years, rates of local and distant cancer control, and patient-reported symptoms related to heart and lung health. Safety is closely monitored, focusing on acute and late side effects affecting the heart and lungs.

Age: 18Years +All GendersPhase 2
125 locations
C

Actively Recruiting

Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.

Age: 18Years +All GendersPhase 2
331 locations
A

Actively Recruiting

Researchers are evaluating the safety and performance of Abbotts commercially available Structural Heart SH devices in real-world hospital settings. This observational registry collects data to meet regulatory requirements, such as the European Union Medical Device Regulations 2017745, by actively monitoring these devices after market approval. The study includes patients undergoing standard care procedures involving Abbott SH devices, with a focus on confirming device safety and performance across multiple device types. Participants receive one or more Abbott SH devices during routine hospital procedures, including Amplatzer Occlusion Devices for septal defects and Epic Surgical Tissue Heart Valve devices for heart valve replacement. The registry enrolls patients either before the procedure or shortly after, depending on the device type, with follow-up visits aligned with standard care schedules. Follow-up may include discharge or 7-day post-procedure visits, short-term 1-3 months, mid-term 6 months, and long-term up to 12 months or even 10 years assessments depending on the device used. A specific surgical valve sub-study collects additional data for certain valve sizes to support regulatory approval in the US. Participants are monitored through their routine care visits, which may occur in person, by phone, or virtually. Data collected include safety and effectiveness outcomes at various time points post-procedure. The registry plans to enroll approximately 500 subjects annually across about 25 global sites, with follow-up duration varying by device type to cover short- and long-term safety and performance. The total study completion is expected by November 2039, allowing extended monitoring of patient outcomes.

All AgesAll Genders
36 locations
E

Actively Recruiting

This research investigates the impact of a team-based kidney care program on adults who have survived moderate to severe acute kidney injury AKI after a hospital stay. The study aims to evaluate how this multidisciplinary approach affects patient-centered outcomes compared to usual care. The goal is to improve recovery and prevent complications after hospital discharge by providing tailored support based on individual risk. Participants are assigned to one of two groups. The intervention group receives risk-based kidney care before leaving the hospital, which may include education, referrals to primary care with medication reviews, or nephrologist-led care combined with remote monitoring for up to 90 days post-discharge. The usual care group receives standard education, laboratory tests, and clinical follow-up after discharge. This pragmatic trial compares these approaches to assess their effects on health outcomes. During the study, participants are monitored for hospital-free days over 90 days, 180 days, and one year. Researchers also track hospital readmissions, death, kidney function changes, recurrence of AKI, chronic kidney disease progression, and cardiovascular events. Follow-up evaluations include laboratory tests, medication reviews, and specialist consultations. The research spans up to one year to assess the long-term effects of the kidney care program on patient health and recovery.

Age: 18Years +All GendersPhase Not Applicable
3 locations
R

Actively Recruiting

Researchers are studying the quality of life effects in men with localized prostate cancer undergoing two different types of radiation therapy. The trial compares near margin-less adaptive radiation therapy ART, which adapts treatments based on ongoing imaging, to the standard stereotactic ablative body radiotherapy SABR given in five sessions. This study aims to see if the shorter ART treatment with smaller radiation margins can reduce side effects and maintain effectiveness compared to standard SABR. Participants are randomly assigned to one of two groups. One group receives near margin-less ART in two treatment sessions spaced at least three days apart, with imaging such as cone beam CT, CT, or MRI to guide therapy. The other group undergoes standard SABR in five sessions spaced at least two days apart, also with CT or MRI scans. Following treatment, patients are monitored regularly with follow-up visits at 1, 3, and 6 months, then every six months for up to five years. Throughout the study, participants complete questionnaires on quality of life, urinary and bowel symptoms, erectile function, and financial impact. Doctors track side effects using standard criteria and monitor cancer outcomes including biochemical recurrence and survival over five years. Imaging and treatment details are recorded to explore relationships with outcomes. This comprehensive monitoring helps assess the benefits and risks of the two radiation approaches over time.

Age: 18Years +MALEPhase Not Applicable
5 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
T

Actively Recruiting

This trial evaluates the effects of high dose intravenous ascorbic acid combined with chemotherapy in patients with relapsed or refractory lymphoma, clonal cytopenia of undetermined significance CCUS, and chronic myelomonocytic leukemia CMML. The study aims to determine response rates and safety of adding ascorbic acid to standard treatments for these blood cancers and related conditions. It also investigates biological markers related to treatment effects and disease progression. Participants receive ascorbic acid intravenously along with various chemotherapy regimens depending on their disease type and study arm. Some arms involve combination chemotherapy with drugs like rituximab, ifosfamide, carboplatin, etoposide, and others, while some focus on ascorbic acid with decitabine or other agents. Treatments are given in cycles, ranging from every 21 days up to 12 cycles or longer, depending on response and tolerance. Some study arms are closed for enrollment, while others remain active. During the study, participants undergo blood tests, bone marrow biopsies, imaging scans such as PETCT or MRI, and heart function tests. Central lines like PICC or portacath may be placed for treatment delivery. Researchers monitor response rates, survival, adverse events, symptom changes, and biological markers throughout treatment and follow-up. After treatment, participants are followed every 3 to 6 months for up to two years to assess long-term outcomes and safety.

Age: 18Years +All GendersPhase 2
4 locations

1-10 of 90

1